Ovarian Cancer
Conditions
Keywords
Homologous Recombination Deficiency Score
Brief summary
This project intends to evaluate the sensitivity of different Homologous Recombination Deficiency (HRD) score to Poly(ADP-ribose) polymerase inhibitor (PARPi) by retrospectively analyzing the tissue samples of patients with ovarian cancer using PARPi, and to determine the cut off value of the HRD score algorithm suitable for the Chinese population, so as to provide evidence for the role of PARPi in ovarian cancer. The screening of the beneficiaries of maintenance therapy provides precise guidance and can be used as a reference for other cancer types.
Interventions
None listed
Sponsors
Xin Wu
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. age ≥ 18 years; 2. high-grade serous/endometrioid epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer; 3. FIGO stage III or IV; 4. at least 6 cycles and no more than 9 cycles First-line platinum-containing chemotherapy; 5. CR or PR after chemotherapy; 6. ECOG 0-1; 7. sufficient biological samples for HRD score detection; 8. patients signed informed consent; 9. good bone marrow function.
Exclusion criteria
1. incomplete follow-up records of survival information; 2. unqualified biological sample quality control
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Homologous Recombination Deficiency score | After the ovarian tissue is obtained, an average of 3 year | Optimize the Homologous Recombination Deficiency scoring algorithm to calculate the Homologous Recombination Deficiency score of each patient's ovarian cancer tissue |
Countries
China
Contacts
Primary ContactXin Wu, PHD
Backup ContactLing Qiu, MD
Outcome results
None listed